# US 2012/0251538 A1 · Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251538 A1
- Document ID: US20120251538A1
- Status: Published application
- Kind: A1
- Application number: 13/509,068
- Filed: 2010-11-12
- Published: 2012-10-04
- Earliest claimed: 2009-11-13
- Assignees: Five Prime Pharmaceutials, Inc.
- Inventors: Thomas Harding; Michael W. Kavanaugh
- Web page: https://patentgrep.com/patent/US20120251538A1

## CPC

- C07K 14/71: for growth factors; for growth regulators
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 35/00: Antineoplastic agents
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A method of treating cancer in a subject comprising:
a) determining whether cells from the cancer comprise a ligand dependent activating mutation in FGFR2; and
b) if the cells comprise a ligand dependent activating mutation in FGFR2, administering a therapeutically effective amount of an FGFR1 ECD to the subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein the ligand dependent activating mutation in FGFR2 is a substitution at at least one position selected from 203, 211, 212, 252, 253, 267, 272, 283, 293, 310, 314, 315, 375, 380, 383, 390, and 392.

### Claim 59 (depends on 57)

The method of claim 57, wherein the ligand dependent activating mutation in FGFR2 is located at the IgII-IgIII hinge region or in the IgIII domain of FGFR2.

### Claim 60 (depends on 59)

The method of claim 59, wherein the ligand dependent activating mutation in FGFR2 is a substitution at at least one position selected from 252, 253, 267, 272, 283, 293, 310, 314, and 315.

### Claim 61 (depends on 59)

The method of claim 59, wherein the ligand dependent activating mutation in FGFR2 is not a substitution from a wild-type amino acid to a cysteine.

### Claim 62 (depends on 57)

The method of claim 57, wherein the cancer is selected from endometrial, breast, gastric, lung, and ovarian cancer.

### Claim 63 (depends on 57)

The method of claim 57, wherein the FGFR1 ECD is an FGFR1 ECD fusion molecule.

### Claim 64 (depends on 63)

The method of claim 63, wherein the FGFR1 ECD fusion molecule comprises an FGFR1 ECD fused to an Fc.

### Claim 65 (depends on 64)

The method of claim 64, wherein the FGFR1 ECD fusion molecule comprises the amino acid sequence of SEQ ID NO: 22.

### Claim 66 (depends on 57)

The method of claim 57, wherein the determining comprises amplification and sequencing.

### Claim 67

A method of treating cancer in a subject comprising:
a) having cells from the cancer tested for the presence of a ligand dependent activating mutation in FGFR2; and
b) if the cells comprise a ligand dependent activating mutation in FGFR2, administering a therapeutically effective amount of an FGFR1 ECD to the subject.

### Claim 68

A method of treating cancer comprising administering a therapeutically effective amount of an FGFR1 ECD to a subject, wherein the cancer has previously been characterized as having a ligand dependent activating mutation in FGFR2.
